Ascendis Pharma Unveils Long-Term Data on Hypoparathyroidism and Achondroplasia Treatments at ASBMR 2026
Event summary
- Ascendis Pharma will present long-term data from Phase 2 and Phase 3 trials of TransCon PTH (palopegteriparatide) for hypoparathyroidism at ASBMR 2026, showing normalization of bone mass and microarchitecture over 5 years.
- The company will also share updates on its achondroplasia programs, including results from the ApproaCH Trial open-label extension and the Phase 2 COACH Trial combining navepegritide with lonapegsomatropin.
- ASBMR 2026 will feature an oral presentation on October 11 and multiple poster sessions from October 8-11.
- TransCon CNP (navepegritide) is under regulatory review in the EU, with a decision expected in Q4 2026.
The big picture
Ascendis Pharma is positioning itself as a leader in rare disease treatments with its TransCon technology platform. The upcoming data presentations at ASBMR 2026 could further solidify its standing in the hypoparathyroidism and achondroplasia markets. The potential EU approval of YUVIWEL would mark a significant expansion of its commercial footprint.
What we're watching
- Regulatory Milestones
- Whether the European Medicines Agency will approve YUVIWEL for achondroplasia in Q4 2026, expanding Ascendis' market reach.
- Clinical Efficacy
- How the long-term data on TransCon PTH will influence treatment paradigms for hypoparathyroidism.
- Combination Therapy Potential
- The pace at which Ascendis can advance its combination therapy approach for achondroplasia.